BioSpace News Archive

Transcat today reported financial results for its second quarter ended September 23, 2017 of fiscal year 2018, which ends March 31, 2018.

amfAR, The Foundation for AIDS Research, announced on Monday the 2017 recipients of the Mathilde Krim Fellowships in Basic Biomedical Research. Named in honor of amfAR Founding Chairman Dr. Mathilde Krim, the Krim Fellowship program supports bright young scientists seeking innovative solutions to HIV/AIDS.

Hutchison China MediTech Limited announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares.

Apollo Endosurgery announced today it has entered into a Registry Funding Agreement with the American Gastroenterological Association (AGA) Center for GI Innovation and Technology to develop and administer a registry to evaluate flexible endoscopic procedures enabled by the OverStitch™ Endoscopic Suturing System.

Alzheon announced that FDA has granted Fast Track designation to its lead clinical investigational drug, ALZ-801, for the treatment of Alzheimer’s disease.

BioTime, Inc., a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release third quarter financial and operating results on Thursday, November 9, 2017, after the close of the U.S. financial markets.

Invacare Corporation today expanded its healthcare informatics offering via the launch of the enhanced Invacare Platinum Mobile Oxygen Concentrator with Connectivity.

Synlogic, a clinical stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that the FDA has granted Orphan Drug Designation to SYNB1618,

Grey Cloak Tech Inc. announced today that it has acquired 100% in an all-stock transaction Eqova Life Sciences, a medically-focused CBD company.

In the third calendar quarter (3Q) and first nine months (9M) of 2017, Utah Medical Products, Inc. achieved results which confirm that the Company is very likely to significantly exceed its previously announced goals for 2017.